Positive Clinical Updates on Vaccine-Based Approaches; Uncovering their Potential in Combination Therapy
Time: 8:45 am
day: Conference Day 1
Details:
- SurVaxM – a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine targeting surviving
- Phase IIa study of surVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma
